Solution conformation of wild-type and mutant IgG3 and IgG4 immunoglobulins using crystallohydrodynamics: possible implications for complement activation.
We have employed the recently described crystallohydrodynamic approach to compare the time-averaged domain orientation of human chimeric IgG3wt (wild-type) and IgG4wt as well as two hinge mutants of IgG3 and an IgG4S331P (mutation from serine to proline at position 331, EU numbering) mutant of IgG4. The approach involves combination of the known shape of the Fab and Fc regions from crystallography with hydrodynamic data for the Fab and Fc fragments and hydrodynamic and small angle x-ray scattering data for the intact IgG structures. In this way, ad hoc assumptions over hydration can be avoided and model degeneracy (uniqueness problems) can be minimized. The best fit model for the solution structure of IgG3wt demonstrated that the Fab regions are directed away from the plane of the Fc region and with a long extended hinge region in between. The best fit model of the IgG3m15 mutant with a short hinge (and enhanced complement activation activity) showed a more open, but asymmetric structure. The IgG3HM5 mutant devoid of a hinge region (and also devoid of complement-activation activity) could not be distinguished at the low-resolution level from the structure of the enhanced complement-activating mutant IgG3m15. The lack of inter-heavy-chain disulphide bond rather than a significantly different domain orientation may be the reason for the lack of complement-activating activity of the IgG3HM5 mutant. With IgG4, there are significant and interesting conformational differences between the wild-type IgG4, which shows a symmetric structure, and the IgG4S331P mutant, which shows a highly asymmetric structure. This structural difference may explain the ability of the IgG4S331P mutant to activate complement in stark contrast to the wild-type IgG4 molecule which is devoid of this activity.
Lu
Yanling
Y
National Centre for Macromolecular Hydrodynamics, University of Nottingham, Sutton Bonington, England.
Harding
Stephen E
SE
Michaelsen
Terje E
TE
Longman
Emma
E
Davis
Kenneth G
KG
Ortega
Alvaro
A
Grossmann
J Günter
JG
Sandlie
Inger
I
García de la Torre
José
J
D000936:Antigen-Antibody Complex / Q000737:chemistry* / Q000276:immunology / Q000648:ultrastructure; D001665:Binding Sites; D003167:Complement Activation / Q000276:immunology; D003198:Computer Simulation; D007074:Immunoglobulin G / Q000737:chemistry* / Q000235:genetics / Q000276:immunology / Q000648:ultrastructure*; D008956:Models, Chemical; D008958:Models, Molecular; D009154:Mutation; D011485:Protein Binding; D011487:Protein Conformation; D013329:Structure-Activity Relationship
D000936:Antigen-Antibody Complex; D007074:Immunoglobulin G
J Mol Biol. 2002 May 24;319(1):9-18
12051932
Biophys J. 1999 Dec;77(6):2902-10
10585914
EMBO J. 1988 Jul;7(7):1989-94
3138110
Q Rev Biophys. 1976 May;9(2):135-80
785525
Clin Exp Immunol. 1991 Apr;84(1):1-8
1707767
Nature. 1988 Apr 21;332(6166):738-40
3258649
Proc Natl Acad Sci U S A. 1981 Jan;78(1):524-8
6787591
J Mol Biol. 2004 May 14;338(5):921-41
15111057
Biophys J. 1999 Jun;76(6):3044-57
10354430
Biophys J. 2006 Sep 1;91(5):1688-97
16766619
J Immunol. 1997 Oct 1;159(7):3372-82
9317136
J Exp Med. 1991 Apr 1;173(4):1025-8
2007852
J Immunol. 1998 Oct 15;161(8):4083-90
9780179
Nature. 1984 Jan 12-18;307(5947):136-40
6690993
Methods Mol Biol. 2004;248:93-113
14970492
Eur Biophys J. 2003 Aug;32(5):477-86
12698288
Biophys J. 2000 Mar;78(3):1606-19
10692345
Mol Immunol. 1987 Aug;24(8):821-9
3657808
Mol Immunol. 1985 Mar;22(3):161-206
3889592
J Mol Biol. 1998 Feb 6;275(5):861-72
9480774
Eur J Immunol. 1994 Oct;24(10):2542-7
7925582
Mol Immunol. 1994 Oct;31(15):1201-10
7935507
J Mol Biol. 2005 Oct 14;353(1):155-73
16157351
Scand J Immunol. 1990 Nov;32(5):517-28
2125362
Acta Crystallogr D Biol Crystallogr. 2001 Jan;57(Pt 1):168-71
11134947
Proc Natl Acad Sci U S A. 1994 Sep 27;91(20):9243-7
7937748
Nature. 1968 Oct 19;220(5164):239-41
4176457
J Biochem Biophys Methods. 1993 Jul;26(4):261-71
8409198
J Mol Biol. 2003 Jun 6;329(3):525-50
12767833
Nature. 1976 Dec 2;264(5585):415-20
1004567
Eur J Immunol. 1991 Jan;21(1):11-6
1703960
Eur J Biochem. 1985 Feb 15;147(1):17-25
3971974
Eur J Immunol. 1993 May;23(5):1098-104
8477804
J Mol Biol. 1999 Mar 12;286(5):1421-47
10064707
Nature. 1992 Nov 26;360(6402):369-72
1448155
Mol Immunol. 1990 Feb;27(2):181-90
2320011
J Exp Med. 1993 Aug 1;178(2):661-7
8340761
J Immunol. 1997 Jan 15;158(2):733-40
8992989
Adv Immunol. 1999;72:191-208
10361576
Mol Immunol. 2000 Nov;37(16):995-1004
11395138
Biopolymers. 2002 Mar;63(3):163-7
11787004
Immunol Today. 1986 Jun;7(6):169-74
25290202
J Mol Biol. 1991 Nov 5;222(1):17-9
1942064
J Immunol. 2006 Jul 15;177(2):1129-38
16818770
J Exp Med. 1987 Nov 1;166(5):1351-61
3500259
Immunology. 1995 Oct;86(2):319-24
7490135
Eur Biophys J. 1997;25(5-6):361-72
9213556
Methods Enzymol. 1989;178:130-44
2601621
Eur J Immunol. 2006 Jan;36(1):129-38
16323243
Eur Biophys J. 1999;28(2):119-32
10028237
Immunol Today. 1986 Jun;7(6):174-8
25290203
J Mol Biol. 1994 Feb 11;236(1):300-9
8107111
Nature. 1993 Jun 17;363(6430):628-30
8510754
Biophys Chem. 2001 Nov 28;93(2-3):181-96
11804725
J Biol Chem. 1970 May 25;245(10):2763-4
5445808
J Appl Crystallogr. 2012 Mar 15;45(Pt 2):342-350
25484842
J Immunol. 2000 Apr 15;164(8):4178-84
10754313
Adv Protein Chem. 1996;49:57-133
8908297
Eur Biophys J. 2003 Aug;32(5):503-10
12811430